[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580139":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":39,"responsibleParty":55,"collaborators":25,"id":57,"slug":25,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":25,"enrollmentInfo":66,"targetDuration":25,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":79,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Insel Gruppe AG, University Hospital Bern","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"26 weeks glucocorticoid","ACTIVE_COMPARATOR","26 weeks glucocorticoid taper",[13],"Drug: Prednisone",{"label":15,"type":16,"description":17,"interventionNames":18},"8 weeks glucocorticoid","EXPERIMENTAL","8 weeks glucocorticoid taper",[13],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Prednisone","Participant randomization to receive shortened (8 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.",[15],null,{"type":21,"name":22,"description":27,"armGroupLabels":28,"otherNames":25},"Participant randomization to receive standard (26 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.",[9],[30],{"name":31,"affiliation":32,"role":33},"Lisa Christ, Dr. med.","Department of Rheumatology and Immunology, Inselspital, University of Bern, Bern, Switzerland","PRINCIPAL_INVESTIGATOR",[35],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","+41 31 63 2 72 29","RI-Studien@insel.ch",[40],{"facility":41,"status":25,"city":42,"state":25,"zip":25,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Department of Rheumatology and Immunology, Inselspital, University of Bern","Bern","Switzerland","CH",{"type":46,"coordinates":47},"Point",[48,49],7.44744,46.94809,{"lat":49,"lon":48},[52,54],{"name":31,"role":36,"phone":53,"phoneExt":25,"email":38},"+41 31 632 7229",{"name":31,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":56,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100580139",false,"NCT06833411","Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone","Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone: a Randomized, Multicenter, Adaptive, Blinded, Phase III Study","GISCO","Inclusion Criteria:\n\n* Patients diagnosed with giant cell arteritis\n* Start of tocilizumab treatment at baseline as part of routine clinical practice\n* Receive ≥ 20 mg\u002Fday prednisone (or equivalent) at baseline\n* Written informed consent\n\nExclusion Criteria:\n\n* Treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) prior to the first dose of tocilizumab.","ALL","50 Years",{"count":67,"type":68},178,"ESTIMATED","INTERVENTIONAL",[71],"PHASE3","The GISCO study plans to determine whether 8-week therapy is just as effective as 26-week cortisone therapy for treating giant cell arteritis\n\n* with tocilizumab,\n* while using less cortisone.",[74],"Giant Cell Arteritis (GCA)",[76,77,22,78],"Tocilizumab","Glucocorticoid","Giant cell arteritis","NOT_YET_RECRUITING","2026-04-30",{"date":82,"type":83},"2026-05-01","ACTUAL",{"date":85,"type":68},"2026-07",{"date":87,"type":68},"2032-08",{"name":5,"class":6},1]